Description
<jats:p>During the 1980s, the free radical, nitric oxide (NO), was discovered to be a crucial signalling molecule, with wide‐ranging functions in the cardiovascular, nervous and immune systems. Aside from providing a credible explanation for the actions of organic nitrates and sodium nitroprusside that have long been used in the treatment of angina and hypertensive crises respectively, the discovery generated great hopes for new NO‐based treatments for a wide variety of ailments. Decades later, however, we are still awaiting novel licensed agents in this arena, despite an enormous research effort to this end. This review explores some of the most promising recent advances in NO donor drug development and addresses the challenges associated with NO as a therapeutic agent.</jats:p><jats:p><jats:italic>British Journal of Pharmacology</jats:italic> (2007) <jats:bold>151</jats:bold>, 305–321; doi:<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1038/sj.bjp.0707224">10.1038/sj.bjp.0707224</jats:ext-link></jats:p>
Journal
-
- British Journal of Pharmacology
-
British Journal of Pharmacology 151 (3), 305-321, 2007-06
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1362544420088244224
-
- ISSN
- 14765381
- 00071188
-
- Data Source
-
- Crossref